Rocky Mountain Cancer Centers Bets on AI to Transform Patient Care

NEW YORK, NY – July 16, 2026 – In a significant move signaling a new chapter for community-based oncology, Rocky Mountain Cancer Centers (RMCC), Colorado's largest multidisciplinary cancer practice, has announced a multi-year partnership with Canopy, a leader in Enterprise AI for oncology. The collaboration will see RMCC integrate Canopy's comprehensive AI platform across its 19 locations, a strategic investment aimed at enhancing patient care, improving operational efficiency, and managing the increasing complexity of modern cancer treatment.

This partnership represents more than just a technology upgrade; it marks a strategic shift for a major regional healthcare provider, placing advanced artificial intelligence at the core of its patient service model. For RMCC, which treats more adult cancers than any other organization in Colorado, the decision reflects a proactive approach to the pressures and opportunities shaping modern healthcare.

"Our commitment to patients is to deliver the best possible care close to home," said Dr. Manojkumar Bupathi, President of Rocky Mountain Cancer Centers. "With Canopy, we're investing in AI-native infrastructure that helps us stay at the forefront of this commitment, from how patients engage with their care teams to clinical monitoring and support for novel therapies, all while empowering our staff with tools and automation."

A Strategic Shift Towards Intelligent Care

The term "Enterprise AI" can feel abstract, but for RMCC, its application is concrete. Canopy's platform is designed to manage the vast and critical landscape of care that happens between patient visits. It functions as an intelligent layer that integrates with existing Electronic Medical Records (EMR), automating and optimizing workflows across triage, patient communications, front office operations, and the pharmacy.

At the heart of the system is a sophisticated Remote Therapeutic Monitoring (RTM) solution. This allows patients to report symptoms in real-time from any device, providing the clinical team with continuous insight into their condition. Instead of waiting for a scheduled appointment or a patient to call when symptoms become severe, an AI-native triage engine systematically analyzes these patient-reported outcomes. It prioritizes urgent issues, alerts the appropriate clinical staff, and provides decision-support pathways, enabling what one study found to be a 93% faster resolution of patient requests.

Beyond symptom management, the platform addresses common operational bottlenecks. It includes features for secure patient messaging and automates pharmacy workflows like adherence monitoring for oral medications and refill management. The partnership also includes the deployment of "Kathy," an AI-powered phone operator built specifically for oncology, designed to manage high call volumes and provide after-hours support, freeing up staff to focus on more complex patient needs.

This holistic approach is a direct response to the escalating complexity of cancer care, which now involves novel treatments like CAR T-cell therapies and bispecific antibodies that require intensive monitoring. By automating routine tasks and providing data-driven insights, the platform aims to equip RMCC's 54 physicians and their support teams to manage this complexity more effectively.

Quantifying the Impact on Patients and Staff

For patients navigating a cancer diagnosis, the period between appointments can be filled with uncertainty and anxiety. This partnership aims to transform that experience by creating a more connected and responsive care journey. Through the RTM system, patients gain a direct and structured line of communication to their care team, ensuring their symptoms are not just heard, but systematically evaluated and addressed. Research shows that for urgent symptom reports using Canopy's platform, the average resolution time is just 15 minutes.

This proactive monitoring is particularly crucial for patients undergoing novel therapies, where early identification of side effects can be critical. The platform provides a framework to expand access to these cutting-edge treatments within a community setting, ensuring patients can receive advanced care while remaining close to their homes and support networks.

For the clinical staff at RMCC, the integration of Canopy's AI promises a significant reduction in administrative burden. The relentless inflow of patient calls, prescription refill requests, and symptom-related queries can lead to staff burnout and divert time away from direct clinical care. By automating and intelligently triaging these tasks, the AI platform acts as a force multiplier. Nurses receive prioritized alerts with decision support, allowing them to intervene more quickly and efficiently. This shift allows highly skilled clinicians to operate at the top of their license, focusing their expertise where it matters most.

"We're proud to partner with Rocky Mountain Cancer Centers, a leading practice known for their leadership and innovation, especially regarding clinical trials and novel therapies," said Lavi Kwiatkowsky, Founder and CEO of Canopy. "Our goal is to deliver on the promise of Enterprise AI in ways that meaningfully improve care for patients and reduce complexity for care teams."

The Evidence and Economics of AI-Driven Oncology

A key driver behind this strategic shift is the growing body of clinical and financial evidence demonstrating the tangible benefits of enterprise AI in oncology. Canopy has been at the forefront of generating this data, with recent findings presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting underscoring the platform's impact.

One study revealed that cancer patients actively using the Canopy RTM platform experienced a 28% reduction in hospitalizations. For a practice, this translates to an estimated annualized cost saving of approximately $3.2 million per 1,000 patients. Another presentation focused on patients receiving immune checkpoint inhibitors, a common but complex class of immunotherapy. The data showed an 82% longer median time before treatment had to be discontinued and a striking 51% lower risk of hospitalization at 12 months. The financial implication is substantial, with estimated annualized savings of around $12.6 million per 1,000 person-years of treatment.

These figures highlight a powerful alignment between improved patient outcomes and financial sustainability—the core principle of value-based care. By keeping patients healthier and out of the emergency room, RMCC can not only enhance quality of life but also reduce the overall cost of care. Furthermore, Canopy's platform helps practices operationalize and automate reimbursement programs for services like Chronic Care Management, creating new, sustainable revenue streams for the crucial work that happens between visits.

A New Standard for Community Cancer Care?

The RMCC-Canopy partnership may well be a bellwether for the broader adoption of AI in community oncology, a sector that delivers the majority of cancer care in the United States. These practices face immense pressure from staffing shortages, rising operational costs, and the rapid pace of therapeutic innovation. AI platforms that promise to enhance efficiency, improve outcomes, and bolster the bottom line are becoming an increasingly compelling proposition.

Canopy's growing footprint, which now supports over 500 sites of care nationwide through partnerships with practices in Ohio, Alabama, and Utah, indicates a clear trend. The company's focus on creating a unified, oncology-specific platform for all between-visit care differentiates it from more generalized EMR vendors or single-point solutions. This specialized, integrated approach appears to be resonating with forward-thinking practice leaders.

Of course, integrating AI into the sensitive domain of cancer care requires careful navigation of ethical and privacy considerations. Ensuring robust data security under HIPAA, maintaining transparency in how AI algorithms assist in decision-making, and preserving the essential human touch in patient interactions are paramount. The model being implemented, where AI augments clinical staff by providing alerts and decision support, represents a crucial human-in-the-loop system. This ensures that technology empowers, rather than replaces, the clinical judgment and empathy that lie at the heart of compassionate cancer care.